Lutetium Lu 177 dotatate

Summary

Lutetium Lu 177 dotatate (Lutathera) is a radiolabeled somatostatin analogue approved for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. It delivers targeted radiation to tumor cells expressing somatostatin receptors, particularly SSTR2. Approval was based on the NETTER-1 Phase III trial demonstrating significant improvement in progression-free survival versus high-dose octreotide LAR.

Mechanism of Action

Dotatate (DOTA-Tyr3-octreotate) binds with high affinity to somatostatin receptors (predominantly SSTR2) overexpressed on neuroendocrine tumor cells. The lutetium-177 radionuclide emits beta particles that cause DNA damage and cell death in receptor-expressing tumor cells and surrounding tissue (crossfire effect).

Routes of Administration

Goals & Uses

• Treatment of somatostatin receptor-positive GEP-NETsOncology / Neuroendocrine Tumor ManagementHigh
• Symptom control in functional NETsSymptom ManagementModerate
• Objective tumor response / tumor shrinkageOncology / Tumor ResponseModerate
• Treatment of other SSTR2-positive tumors (off-label/investigational)Oncology / Investigational UseLow
• Improvement of progression-free survival in NETsOncology / Disease ControlHigh

Contraindications

• Previous maximum radiation dose to critical organs (kidneys, bone marrow)Radiation OncologyHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Severe renal impairment (eGFR <30 mL/min/1.73m²)RenalHigh
• BreastfeedingPopulationHighPotential transfer into breast milk or insufficient safety data
• Hypersensitivity to dotatate or Lu-177 componentsAllergy / ImmunologyHigh

Adverse Effects

• HepatotoxicityHepaticUncommonLiver injury or dysfunction
• Myelosuppression (thrombocytopenia, anemia, lymphopenia)HematologicCommon
• Nephrotoxicity / renal impairmentRenalUncommon
• Nausea and vomitingGastrointestinalCommon
• FatigueGeneralCommonLow energy or tiredness
• Radiation-induced myelodysplastic syndrome / acute leukemiaHematologic / Secondary MalignancyRare

Drug Interactions

• Myelosuppressive agents (chemotherapy, immunosuppressants)Moderate
• Long-acting somatostatin analogues (e.g., octreotide LAR)Moderate
• Nephrotoxic agents (e.g., aminoglycosides, NSAIDs, cisplatin)High
• Short-acting somatostatin analogues (e.g., octreotide SC)High

Population Constraints

• Patients with moderate renal impairment (eGFR 30-60 mL/min/1.73m²)RenalRelative
• Pediatric patientsAgeRelative
• Male patients with female partners of childbearing potentialReproductiveRelative
• Patients with significant bone marrow involvement or prior myelotoxic therapyHematologicRelative
• Women of childbearing potentialReproductiveRelative

Regulatory Status

• European UnionApprovedApproved: Treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2), somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adultsEMA approved September 26, 2017. Orphan designation. Centralized marketing authorization. Conditional approval upgraded to full authorization.
• United StatesApprovedApproved: Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adultsFDA approved January 26, 2018. Orphan drug designation. Requires REMS-like handling per radiation safety guidelines. Manufacturer: Advanced Accelerator Applications (AAA), a Novartis company.
• United KingdomApprovedApproved: Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adultsApproved by MHRA post-Brexit reliance on EMA data. NICE recommended with conditions for NHS use in England.

FDA approved January 2018 (US); EMA approved September 2017 (EU). Designated as orphan drug in both US and EU. Requires specialized nuclear medicine facilities and radiation safety protocols. Must be administered with concomitant long-acting octreotide LAR.

Evidence & Sources

No sources recorded yet.